Ranibizumab and bevacizumab for neovascular age-related macular degeneration

New England Journal of Medicine

Volumn 364, Issue 20, 2011, Pages 1897-1908

  Martin, Daniel F ^a   Maguire, Maureen G ^b   Ying, Gui Shuang ^b   Grunwald, Juan E ^b   Fine, Stuart L ^c   Jaffe, Glenn J ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEATH; DRUG FATALITY; ENDOPHTHALMITIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART DISEASE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; PNEUMONIA; PRIORITY JOURNAL; PSEUDOENDOPHTHALMITIS; RANDOMIZED CONTROLLED TRIAL; RETINA; RETINA MACULA AGE RELATED DEGENERATION; SINGLE BLIND PROCEDURE; STROKE; THICKNESS; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; URINARY TRACT INFECTION; VEIN THROMBOSIS; VISUAL ACUITY;

EID: 79956218863     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1102673     Document Type: Article

References (22)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
3. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5. (Pubitemid 41073112)
4. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.
5. Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service Part B claims file. Am J Ophthalmol 2011;151:887-95.
6. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable-dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.
7. Martin DF, Maguire MG, Fine SL. Identifying and eliminating the road-blocks to comparative-effectiveness research. N Engl J Med 2010;363:105-7.
8. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol 2003;135:194-205. (Pubitemid 36151797)
9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106. [Erratum, BMJ 1994;308:1540.]
10. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Points to consider on switching between superiority and non-inferiority. CMP/EWP/482/99. July 27, 2000. (http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003658.pdf.)
11. Data analysis, statistical issues, and data monitoring. In: Comparison of Age-related Macular Degeneration Treatments Trials (CATT). CATT: Lucentis-Avastin trial: manual of procedures. May 2010: 10-1-10-14. (http://www.med.upenn.edu/cpob/studies/documents/CATTManualofProceduresMay2010- 000.pdf.)
12. Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-6. (Pubitemid 12080556)
13. Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley, 1987.
14. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
15. Rosner B, Glynn RJ, Lee ML. Incorporation of clustering effects for the Wilcoxon rank sum test: a large-sample approach. Biometrics 2003;59:1089-98. (Pubitemid 38021239)
16. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220.
17. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, shamcontrolled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48.
18. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009;116:1731-9.
19. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study. Ophthalmology 2010 December 9 (Epub ahead of print).
20. Genentech. Avastin labeling text (FDA approval date of May 2009). (http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125085s0169lbl.pdf.)
21. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300:2277-85.
22. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273-9. [Erratum, Arch Ophthalmol 2010;128:1623.]